Toripalimab-tpzi is a programmed death receptor-1 (PD-1) blocking antibody. Toripalimab-tpzi
is a humanized immunoglobulin G4 (IgG4) kappa immunoglobulin that has a predicted
molecular weight of approximately 150 kDa. It is expressed in a recombinant Chinese Hamster
Ovary (CHO) mammalian cell expression system.
LOQTORZI (toripalimab-tpzi) injection is a sterile, preservative-free, clear to slightly
opalescent, colorless to slightly yellow solution for intravenous use supplied in a single-dose
vial. Each vial contains 240 mg of LOQTORZI in 6 mL of solution. Each mL of solution
contains 40 mg toripalimab-tpzi, citric acid monohydrate (0.51 mg), mannitol (25 mg),
polysorbate 80 (0.20 mg), sodium chloride (2.92 mg), sodium citrate (4.65 mg), and Water for Injection, USP, at pH 6.0
Injection: 240 mg/6 mL (40 mg/mL) solution in a single-dose vial
In combination with cisplatin and gemcitabine: • 240 mg intravenously every three weeks As a single agent: • 3 mg/kg intravenously every two weeks
LOQTORZI is indicated, in combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or with recurrent, locally advanced nasopharyngeal carcinoma
